 So, AL amyloidosis is a rare disease. There are some patients with myeloma, about 10% of myeloma patients that will develop also AL amyloidosis or have concomitant AL amyloidosis. But most patients with AL amyloidosis are primary AL amyloidosis patients. The AL stands for amyloid lambda or kappa, light chain amyloidosis. In the product of the plasma cell, the light chains which are secreted by the plasma cells, they aggregate within organs, mostly the heart, the kidneys and actually any organ in the body and cause damage to this organ. So AL amyloidosis is a disease where the malignant plasma cell secretes a certain protein that causes damage. AL amyloidosis is diagnosed first of all by suspicion and then we're trying to prove just like any other malignant disease by a biopsy to find the amyloid. And we are trying to diagnose this through either directly from the organs, but if it's the heart or the kidney then the biopsy is more difficult. We try to assess it by checking the presence of amyloid within the fat, with a fat pet biopsy or a soft tissue biopsy and we dye them with a special dye which is called congorade which is very specific and sensitive to find this amyloidosis when the protein is within the fat pet or the tissue. So both diseases are diseases of the plasma cells. The plasma cell is the sick cell. In AL amyloidosis it proliferates slow and in myeloma it proliferates fast but the cell is the same cell and this is why even some patients with myeloma will have amyloidosis. Why these diseases do not behave exactly the same we don't really know. So because it's the sick plasma cell as we said before the treatments are basically the same treatments. The only problem with the treatments are that treatments that are designed for myeloma are not designed for AL amyloidosis patients in terms of their toxicity. So because these patients will have cardiac toxicity, they will have congestive heart failure, when you give them treatments they might deteriorate faster than myeloma patients and you need to be more careful with the treatments but basically the same chemotherapy, the same novel agents are used for myeloma, they're used for AL amyloidosis as well. So there are various clinical trials running for AL amyloidosis but because it's a rare disease we're talking about a disease that occurs in about 10 per million patients. There aren't too many clinical trials. The clinical trials are designed today are trying to test both to see if the same substances that we use for myeloma are good enough or not toxic, too toxic for AL amyloidosis patients. There are also trials of medications trying to take the amyloid out of the system. Up till now unfortunately these trials failed so but there are still ongoing trials with newer medications, hopefully they will work as well. I think patient advocacy is extremely important. We work as physicians in very close collaborations to patients advocacy groups in order to promote the education of both the patients and the physicians, general physicians as well as hematologists to treat better and to find and diagnose better the patients, to diagnose them earlier to give them better treatment in the future and of course to promote medications and to promote patient oriented results of trials to to get the treatments to aid the patients even more than they are now. I myself am an amyloidosis patient for 10 years and as such faced all the challenges possible and experience of 10 years of having the disease and also learned a lot about the disease from different articles and because it is an orphan disease and it's very rare and the most important changes we have in this disease are connected with diagnosis of the disease, awareness about the disease both in the public and the potential patients as well as in the medical community and the difference in treatment between rural places in a country and central places in the country so all these issues that I pointed out should be tackled and take care of by an amyloidosis association in Europe the problem is that there are very few amyloidosis organizations and because MP is myeloma organization and myeloma is very it's very similar to amyloidosis many points getting even the same treatment and about 10 to 15 percent of myeloma patients get sometimes in the time span amyloidosis I think that the myeloma organizations are the right organization that could help to create amyloidosis organization over Europe or represent amyloidosis patients themselves.